KBY Biotech Indexv0.0.34
Search
← Pipeline|GLS-7714

GLS-7714

Approved
By Gelesis
Source: Trial-derived·Trials: 2
Modality
Small Molecule
MOA
DLL3 ADC
Target
KRASG12C
Pathway
Hedgehog
ALL
Development Pipeline
Preclinical
~Jan 2015
→ ~Apr 2016
Phase 1
~Jul 2016
→ ~Oct 2017
Phase 2
~Jan 2018
→ ~Apr 2019
Phase 3
~Jul 2019
→ ~Oct 2020
NDA/BLA
~Jan 2021
→ ~Apr 2022
Approved
Jul 2022
ApprovedCurrent
NCT05260658
2,523 pts·ALL
2022-07→TBD·Recruiting
NCT05991387
1,809 pts·ALL
2024-10→TBD·Completed
4,332 total pts1 indication
CompletedCurrentUpcoming
Catalysts (1)
2025-09-176mo agoOrphan Drug· ALL
Trial Timeline
Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q4
Approved
Recruit…
Approved
Complet…
Catalysts
Orphan Drug
2025-09-17 · 6mo ago
ALL
RecruitingCompleted|StartCompletionToday
Trials (2)
NCTPhaseIndicationStatusNEP
NCT05260658ApprovedALLRecruiting2523Safety
NCT05991387ApprovedALLCompleted1809PANSS
Competitors (10)
DrugCompanyPhaseTargetMOA
JNJ-179Johnson & JohnsonApprovedKRASG12CBETi
NVS-4076NovartisPreclinicalTROP-2DLL3 ADC
RimamavacamtenMerck & CoPhase 1PI3KαDLL3 ADC
BMY-4586Bristol-Myers SquibbPreclinicalKRASG12CIL-13i
DoxarapivirBristol-Myers SquibbPhase 3KRASG12CSOS1i
AMG-9654AmgenPhase 2GPRC5DDLL3 ADC
AMG-4531AmgenPhase 2/3KRASG12CPRMT5i
REG-8074RegeneronPhase 2/3KRASG12CCAR-T BCMA
VRT-1891Vertex PharmaPhase 1KRASG12CPRMT5i
PemitapinarofBeiGeneApprovedKRASG12CWRNi